Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03681535|
Recruitment Status : Recruiting
First Posted : September 24, 2018
Last Update Posted : August 5, 2020
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity .
Hypothesis: The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET-CT scan following rituximab - containing chemotherapy.
|Condition or disease||Intervention/treatment||Phase|
|Diffuse Large B Cell Lymphoma||Radiation: Radiation Therapy||Not Applicable|
Chemotherapy followed by consolidation radiation therapy (RT) is a recognized treatment paradigm for DLBCL. This was initially established based on the results of 2 randomized trials conducted in the 1980s-1990s. In these studies patients were treated with 30Gy after chemotherapy (ECOG study) or 40-55Gy (SWOG study). A British National Lymphoma Investigation study showed no difference in freedom from local progression, progression-free survival or overall survival in between patients receiving 30Gy and 40-45Gy. Additionally systemic therapy for DLBCL has significantly improved since these initial studies, with the addition of rituximab to standard chemotherapy.
In a phase II study at Duke University patients with DLBCL NOS or primary mediastinal B-cell lymphoma were treated to 19.5-20Gy after achieving complete response to 4-6 cycles of chemotherapy containing rituximab. With a median follow-up of 43 months, there was only 1 local recurrence. The 5-year local control rate was 98%. Progression-free and overall survival at 5 years was 81% and 88%. Therefore, there is emerging evidence of long term favorable outcomes in localized DLBCL, while decreasing the risk of late effects by reducing the dose and volume of RT.
All participants will receive 20Gy instead of 30-36Gy after completion of at least 3 cycles of rituximab with combination chemotherapy. Participants must have a negative post chemotherapy PET-CT to participate in this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma|
|Actual Study Start Date :||February 13, 2019|
|Estimated Primary Completion Date :||November 2027|
|Estimated Study Completion Date :||November 2032|
Experimental: Single arm interventional study
RT to 19.5-20Gy is given after 3 cycles of rituximab containing chemotherapy. RT is administered daily, 5 days per week in 1.5-2Gy fractions (treatments).
Radiation: Radiation Therapy
This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve complete response and have a negative post-chemotherapy PET scan following 3 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
- Local control rate [ Time Frame: 5 years ]Local control rate of 95% measured by standard of care imaging obtained per the National Comprehensive Cancer Network guidelines
- Disease-free survival [ Time Frame: 5 years ]Disease-free survival (DFS) will be defined as the time from on-study to first disease progression or death due to any cause, whichever comes first.
- Overall Survival [ Time Frame: 5 years ]Overall survival will be defines as the time from on-study to death due to any cause.
- Patterns of failure [ Time Frame: 5 years ]To examine patterns of failure we, we will tabulate the various ways that patients failed, up until the time of analysis. For example, these ways will include local only, local + distant, and distant only.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03681535
|Contact: Tykeytra Dale, BSN MS||919-668-3726||Tykeytra.email@example.com|
|Contact: Jennifer Mewshaw, MS NP||919 668 5211||Jennifer.Mewshaw@duke.edu|
|United States, Massachusetts|
|Dana Farber Cancer Institute||Recruiting|
|Boston, Massachusetts, United States, 02215|
|Contact: Patrick Boyle 617-582-8918 firstname.lastname@example.org|
|Principal Investigator: Andrea Ng, MD MPH|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Clinical Trials Referral Office 855-776-0015 Haen.Jennifer@mayo.edu|
|Principal Investigator: Scott Stafford M.D. (Rochester MN)|
|Sub-Investigator: William G Rule M.D. (Scottsdale AZ)|
|Sub-Investigator: Jennifer L Peterson M.D. (Jacksonville FL)|
|United States, New York|
|University of Rochester James P. Wilmot Cancer Institute||Recruiting|
|Rochester, New York, United States, 14642|
|Contact: Jessica Mackowiak (Ellis) 585-275-2224 jessica_ellis@URMC.Rochester.edu|
|Principal Investigator: Louis Constine, MD|
|United States, North Carolina|
|Duke University Medical Center||Recruiting|
|Durham, North Carolina, United States, 27710|
|Contact: Clinical Trials Office 919-668-3726|
|Principal Investigator: Christopher Kelsey, MD|
|United States, Texas|
|MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Charles J Masino 713-745-0194 email@example.com|
|Contact: Irina Yi Chen YChen39@mdanderson.org|
|Principal Investigator: Chelsea C Pinnix, MD PhD|
|University Hospital Motol||Recruiting|
|Contact: Monika Stepanova firstname.lastname@example.org|
|Principal Investigator: Katerina Dedeckova, M.D.|
|University of Torino||Recruiting|
|Contact: Gabriella Furfaro|
|Principal Investigator: Ricardo Umberto, M.D.|
|Contact: Keisuke Sasai, M.D. Ph.D. 81-3-3813-3111 email@example.com|
|Principal Investigator: Keisuke Sasai, M.D. Ph.D.|
|Korea, Republic of|
|Yonsei University Health System||Recruiting|
|Seoul, Korea, Republic of|
|Contact: Hong In Yoon, .M.D. Ph.D. (+82-2)2228-8095 YHI0225@yuhs.ac|
|Principal Investigator: Hong In Yoon, M.D. Ph.D|
|National Cancer Center of Singapore||Recruiting|
|Contact: Yeoh Kheng Wei, M.D. +65-6436 8000 firstname.lastname@example.org|
|Principal Investigator: Yeoh Kheng Wei, M.D.|
|Principal Investigator:||Christopher Kelsey, MD||Duke University Health System|